Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)

PHASE4CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

March 25, 2022

Primary Completion Date

August 30, 2022

Study Completion Date

August 30, 2022

Conditions
Vaccines, CombinedHexavalent Vaccine
Interventions
BIOLOGICAL

Vaxelis™

Vaxelis™ 0.5 mL sterile suspension in prefilled syringe for intramuscular administration.

Trial Locations (13)

15706

CHUS - Hospital Clinico Universitario-Servicio de Pediatría ( Site 0001), Santiago de Compostela

28046

Hospital Universitario La Paz-Pediatria y Enfermedades Infecciosas ( Site 0011), Madrid

28938

Hospital Universitario HM Puerta del Sur-Pediatrics ( Site 0005), Madrid

29200

Hospital Antequera-Pediatrics Unit ( Site 0004), Antequera

38448

Kinderärztliche Gemeinschaftspraxis ( Site 0057), Wolfsburg

41014

Instituto Hispalense de Pediatria- IHP1 ( Site 0006), Seville

41236

Gemeinschaftspraxis Matthias Donner & Dr. Martin Lüchtrath ( Site 0052), Mönchengladbach

49565

Gemeinschaftspraxis Dres. Adelt, Mettlich-Lambrecht und Denneberg ( Site 0053), Bramsche

50354

Kinder- und Jugendärzte Hürth-Park ( Site 0054), Hürth

Private Practice - Dr. Petri, Kinderarztpraxis ( Site 0056), Hürth

52146

Kinderärzte im Recker Park ( Site 0058), Würselen

70124

A.O.U.C. Policlinico di Bari-Hygiene ( Site 0105), Bari

90127

A.O.U. Policlinico Paolo Giaccone ( Site 0102), Palermo

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY